Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-1 (vilobelimab) as glucocorticoid replacement in active GPA and MPA
2018-000768-27Phase 2Completed
- Sponsor
- InflaRx
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilobelimab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by InflaRx. Primary endpoint: Primary efficacy endpoint. Started Dec 2018; status: completed.
02
Drugs
vilobelimab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2018-000768-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000768-27.